)
Visual21 Nov 2025
Data center suppliers
DiaMedica Therapeutics (DMAC) investor relations material
DiaMedica Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
DM199, a recombinant KLK1, is advancing in clinical programs for preeclampsia and acute ischemic stroke, with encouraging interim results, ongoing trial expansions, and a preclinical program for severe acute pancreatitis (DM300).
DM199 demonstrated statistically significant, dose-dependent reductions in blood pressure and improved placental perfusion in preeclampsia patients, with a favorable safety profile and no placental transfer; further study phases are underway.
U.S. phase II preeclampsia trial preparations are underway following a productive pre-IND FDA meeting, focusing on early onset patients with high unmet need.
The ReMEDy2 Phase 2/3 trial for stroke is ongoing, nearing 50% of interim enrollment target, but faces slower-than-expected site activations and enrollment, prompting global expansion.
Screening for Part 3 (fetal growth restriction) in the preeclampsia program to begin soon, with protocol amendments for Parts 1b and 2 underway.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $55.3 million as of September 30, 2025, up from $30 million at June 30, 2025, due to a July private placement.
Net loss was $8.6 million for Q3 2025 and $24.0 million for the nine months ended September 30, 2025, both higher than the prior year periods.
R&D expenses increased to $6.4 million for Q3 and $17.9 million for the nine months, driven by clinical trial progress and team expansion.
General and administrative expenses rose to $2.6 million for Q3 and $7.3 million for the nine months, mainly due to higher share-based compensation and personnel costs.
Net cash used in operating activities was $21.3 million for the nine months ended September 30, 2025, compared to $15.6 million in 2024.
Outlook and guidance
Cash runway is expected to fund planned clinical studies and operations into the second half of 2027.
Completion of the preeclampsia expansion cohort is anticipated in the first half of 2026.
Interim analysis for the ReMEDy2 stroke trial, based on 200 patients, is expected in the second half of 2026.
Additional capital will be needed to complete development and commercialization; future funding requirements depend on trial progress and market conditions.
U.S. Preeclampsia trial: site selection strategy
Stroke trial: impact of new enrollment strategies
Preeclampsia: rationale for IV-only dosing in Part 1b
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next DiaMedica Therapeutics earnings date
Q4 202517 Mar, 2026
Next DiaMedica Therapeutics earnings date
Q4 202517 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious diseases, with an emphasis on acute ischemic stroke (AIS) and cardio-renal diseases. The company is dedicated to improving patient outcomes by advancing its lead product candidate, DM199, which is a synthetic version of the human tissue kallikrein-1 (KLK1) protein. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage